Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1980 Aug;69(4):631–638. doi: 10.1111/j.1476-5381.1980.tb07914.x

The effect of baclofen on the cardiovascular system of the rat.

L A Chahl, S B Walker
PMCID: PMC2044298  PMID: 6108141

Abstract

1 The cardiovascular responses to baclofen were investigated in anaesthetized rats. 2 Low doses of baclofen (less than 5 X 10(-8) mol), given intravenously, produced a transient fall in blood pressure and heart rate. Higher doses (greater than 5 X 10(-7) mol) produced a marked and prolonged increase in blood pressure accompanied by a rise in heart rate and cutaneous arterial dilatation. 3 The pressor and heart rate responses exhibited tachyphylaxis, and were abolished by hexamethonium, cervical cord section, reserpine-treatment and by a combination of alpha- and beta-adrenoceptor antagonists. 4 It is concluded that the increases in blood pressure and heart rate produced by high doses of baclofen are of central sympathetic origin.

Full text

PDF
631

Images in this article

635Figure 4
on p.635

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benecke R., Meyer-Lohmann J. Effects of an antispastic drug (beta-(4-chlorophenyl)-gamma-aminobutyric acid) on Renshaw cell activity. Neuropharmacology. 1974 Nov;13(10-11):1067–1075. doi: 10.1016/0028-3908(74)90097-5. [DOI] [PubMed] [Google Scholar]
  2. Chahl L. A., Ladd R. J. The effects of prostaglandins E1, E2 and F2alpha on the cutaneous vasculature of the rat. Br J Pharmacol. 1976 Mar;56(3):317–322. doi: 10.1111/j.1476-5381.1976.tb07645.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Curtis D. R., Duggan A. W., Felix D., Johnston G. A. Bicuculline, an antagonist of GABA and synaptic inhibition in the spinal cord of the cat. Brain Res. 1971 Sep 10;32(1):69–96. doi: 10.1016/0006-8993(71)90156-9. [DOI] [PubMed] [Google Scholar]
  4. Fotherby K. J., Morrish N. J., Ryall R. W. Is Lioresal (Baclofen) an antagonist of substance P? Brain Res. 1976 Aug 20;113(1):210–213. doi: 10.1016/0006-8993(76)90022-6. [DOI] [PubMed] [Google Scholar]
  5. Gianutsos G., Moore K. E. Tolerance to the effects of baclofen and gamma-butyrolactone on locomotor activity and dopaminergic neurons in the mouse. J Pharmacol Exp Ther. 1978 Dec;207(3):859–869. [PubMed] [Google Scholar]
  6. Olpe H. R., Demiéville H., Baltzer V., Bencze W. L., Koella W. P., Wolf P., Haas H. L. The biological activity of d- and l-baclofen (Lioresal). Eur J Pharmacol. 1978 Nov 1;52(1):133–136. doi: 10.1016/0014-2999(78)90032-8. [DOI] [PubMed] [Google Scholar]
  7. Persson B., Henning M. Cardiovascular effects of baclofen in the rat. J Pharm Pharmacol. 1979 Nov;31(11):799–800. doi: 10.1111/j.2042-7158.1979.tb13667.x. [DOI] [PubMed] [Google Scholar]
  8. Saito K., Konishi S., Otsuka M. Antagonism between Lioresal and substance P in rat spinal cord. Brain Res. 1975 Oct 24;97(1):177–180. doi: 10.1016/0006-8993(75)90928-2. [DOI] [PubMed] [Google Scholar]
  9. Waldmeier P. C., Fehr B. Effects of baclofen and gamma-hydroxybutyrate on rat striatal and mesolimbic 5-HT metabolism. Eur J Pharmacol. 1978 May 15;49(2):177–184. doi: 10.1016/0014-2999(78)90075-4. [DOI] [PubMed] [Google Scholar]
  10. Waldmeier P. C., Maitre L. Effects of baclofen on dopamine metabolism and interaction with neuroleptic effects. Eur J Pharmacol. 1978 Jan 15;47(2):191–200. doi: 10.1016/0014-2999(78)90390-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES